Citizens Financial Group Inc. RI Has $36.24 Million Holdings in Johnson & Johnson $JNJ

Citizens Financial Group Inc. RI increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 18.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 195,465 shares of the company’s stock after buying an additional 31,130 shares during the period. Citizens Financial Group Inc. RI’s holdings in Johnson & Johnson were worth $36,243,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $27,000. Clayton Financial Group LLC acquired a new position in Johnson & Johnson during the third quarter worth approximately $28,000. Semmax Financial Advisors Inc. raised its stake in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares during the period. GFG Capital LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $35,000. Finally, Signature Resources Capital Management LLC boosted its stake in shares of Johnson & Johnson by 262.9% during the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after acquiring an additional 184 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 2.3%

Shares of JNJ opened at $218.53 on Thursday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $218.86. The firm’s 50 day moving average is $204.52 and its 200-day moving average is $186.04. The stock has a market capitalization of $526.51 billion, a PE ratio of 21.09, a P/E/G ratio of 2.19 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.76 by $0.04. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $23.99 billion for the quarter, compared to the consensus estimate of $23.73 billion. During the same quarter in the prior year, the business posted $2.42 earnings per share. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analysts Set New Price Targets

A number of research firms recently weighed in on JNJ. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 14th. Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $193.00 to $208.00 and gave the stock a “market perform” rating in a report on Friday, January 9th. Guggenheim increased their price target on shares of Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a report on Friday, December 5th. Finally, Argus set a $210.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $213.33.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Phase 3 MajesTEC-9 topline: TECVAYLI (teclistamab) monotherapy showed a 71% reduction in risk of progression or death and a 40% reduction in risk of death versus standard of care in early-relapse, largely anti‑CD38/lenalidomide‑refractory myeloma — a potentially significant new earlier-line oncology opportunity that can drive revenue and R&D upside. TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
• Positive Sentiment: Delaware court orders recalculation of damages in Auris/robotics case — the state’s top court overturned part of a ~$1B award and ordered a recalculation that could materially reduce J&J’s payout exposure, lowering legal risk on the balance sheet. Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
• Positive Sentiment: MedTech momentum: Zacks highlights growth driven by cardiovascular strength and new product rollouts, supporting the MedTech segment’s contribution even as China weakness lingers — a constructive signal for recurring revenue. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?
• Positive Sentiment: Psychiatry pipeline/data: New CAPLYTA and SPRAVATO analyses being presented at ACNP reinforce J&J’s CNS franchise and could support future label or adoption upside. Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
• Neutral Sentiment: Company expected to report quarterly results this week — keep an eye on guidance, MedTech trends and margins; earnings timing may create short-term volatility but is routine. Johnson & Johnson (JNJ) Projected to Post Quarterly Earnings on Wednesday
• Neutral Sentiment: Investor attention spikes: Zacks notes heavy search/interest in JNJ — increased attention can amplify moves around data and earnings. Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
• Neutral Sentiment: Dividend visibility: JNJ features in dividend-focused lists (Dogs of the Dow coverage); this underpins income investor interest but is unlikely to move shares materially on its own. The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8%
• Negative Sentiment: Zacks preview flags J&J may lack the setup for an earnings beat next week — if results or guidance disappoint, that could reverse some of today’s gains. Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.